阿尔茨海默病的饮食模式分析涉及叶酸-B12-homocysteine轴对认知结果的性别差异
Chi-Ping Ting1,2, Mi-Chia Ma3, Hsin-I Chang4
1Department of Nursing, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 83301, Taiwan.
Nutrients
|March 13, 2024
概括
饮食模式和血液中的维生素水平会影响阿尔茨海默病 (AD) 的认知. 某些特定的营养物质,如B12和同类氨酸,对阿尔茨海默病患者的认知功能产生性别特异性影响.
科学领域:
- 神经科学是一个神经科学.
- 营养科学 营养科学
- 老年学是指老年学的学科.
背景情况:
- 阿尔茨海默病 (AD) 的认知障碍与维生素B12和叶酸的低含量,以及高水平的同类半氨酸有关.
- 了解饮食,这些血液标记物和认知之间的相互作用对于AD管理至关重要.
研究的目的:
- 为了研究饮食模式,血中叶酸-B12-同类半氨酸水平和AD患者的认知功能之间的关联.
- 探索这些关系中的潜在的性别特异性差异.
主要方法:
- 对592名阿尔茨海默氏症患者 (246名男性,346名女性) 的横截面研究.
- 收集的数据包括人口统计,血液资料,认知的迷你心理状态检查 (MMSE) 和食物频率问卷 (FFQ).
- 使用了结构方程建模 (SEM) 和性别分层回归分析.
主要成果:
- 较高的MMSE得分与较高的咖啡/茶摄入量,教育程度,BMI和年轻年龄相关.
- 饮食因素 (脱脂牛奶,猪肉,咖啡/茶) 和血液特征 (homocysteine,B12,叶酸) 直接影响了认知结果.
- 饮食对认知的影响并非由叶酸-B12-homocysteine水平介导.
- 维生素B12直接影响男性的认知能力,而同型半氨酸对女性的认知能力更为关键.
结论:
- 饮食模式和血液样本都与阿尔茨海默病的认知功能有显著的关联.
- 饮食和营养水平 (B12,同类蛋白) 对认知的影响存在性别差异.
- 需要进一步的多中心纵向研究来验证这些发现,并改善痴呆症患者的营养护理.
关键词:
阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12饮食模式的饮食模式性别影响影响性别影响同型半氨酸同型半氨酸更多相关视频
03:19Author Spotlight: Studying the Impact of Maternal Dietary Deficiencies on Long-Term Offspring Health Outcomes
Published on: June 28, 2024
413
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
14.9K
相关概念视频
Alzheimer's Disease: Overview
475
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
475
Alzheimer's Disease: Treatment
186
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
186
